31.08.2013 Views

Experimental infection and protection against ... - TI Pharma

Experimental infection and protection against ... - TI Pharma

Experimental infection and protection against ... - TI Pharma

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

138 Chapter 7<br />

Figure 2. Parasite kinetics of strains NF135.C10 <strong>and</strong> NF54 assessed by<br />

thick smear <strong>and</strong> quantitative real-time PCR. Volunteers were infected by<br />

bites of mosquitoes infected with either NF135.C10 or NF54. (A) Percentage<br />

of volunteers infected with NF135.C10 (red, n=5) or NF54 (black, n=5)<br />

becoming thick smear positive, followed up up to 21 days after <strong>infection</strong>.<br />

(B) Parasitemia of volunteers until thick smear positivity, measured by<br />

qPCR, is shown as geometric mean <strong>and</strong> 95% confidence interval for<br />

volunteers infected with NF135.C10 (red) <strong>and</strong> NF54 (black), <strong>and</strong> historical<br />

controls infected with NF54 (grey area, n=48).<br />

The drug sensitivity profile of NF135.C10 is similar to NF54 for atovaquone,<br />

proguanil, DHA <strong>and</strong> lumefantrine, but NF135.C10 is more than 8-fold less sensitive<br />

to chloroquine than NF54. Comparison of NF135.C10 <strong>and</strong> NF54 genotypes

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!